Announcements Trials
Browse Landscape

Phase

Phase 1 24Phase 1/2 16Phase 2 11Phase 4 2Phase 3 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Myeloid 1

Conditions

Neoplasms 66Breast Neoplasms 64Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 40Neoplasm Metastasis 23Colorectal Neoplasms 21Multiple Myeloma 20Pain 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Anemia 16Keratosis, Actinic 15Lung Neoplasms 14Cancer Pain 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 11Leukemia 11Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Carcinoma 9Neuroendocrine Tumors 8Melanoma 8Lymphoma 8Ovarian Neoplasms 7Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Recurrence 6Gastrointestinal Stromal Tumors 6Stomatitis 5Stomach Neoplasms 5

Interventions

trametinib 1naxitamab 1dabrafenib 1Isotretinoin 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Neuroblastoma × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT06047535 2023-09-21

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

SciClone Pharmaceuticals

Phase 4 Not yet recruiting
62 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡